Tarceva Sales Effort Will Be Led By Genentech; OSI To Provide 25% Of Reps

An amendment to the companies' 2001 Tarceva development and marketing agreement clarifies responsibilities for each party upon FDA approval of the oncologic. OSI will be responsible for manufacturing commercial supply; the company plans to outsource production to third parties.